It’s a funny old world sometimes… I was planning to post a mini series on immuno-oncology presentations from ESMO this week and review what we had learned from the new data, good and not so good. This morning’s sudden announcement from Genentech regarding their latest collaboration is therefore rather timely:

“An exclusive worldwide licensing agreement and research collaboration with NewLink Genetics for the discovery and development of IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitors for the potential treatment of cancer.”

There are a number of reasons why they might do this that make a lot of solid scientific sense.

To learn more about our insights, subscribers can log-in.

This content is restricted to subscribers

Posted by